HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports.

Several other equities research analysts also recently issued reports on the company. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Price Performance

ESPR opened at $2.17 on Friday. The firm has a market capitalization of $427.58 million, a P/E ratio of -3.39 and a beta of 1.01. The stock has a fifty day moving average of $2.45 and a 200-day moving average of $2.18. Esperion Therapeutics has a 12-month low of $1.58 and a 12-month high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. BOKF NA bought a new position in shares of Esperion Therapeutics during the 2nd quarter valued at $26,000. Xponance Inc. bought a new position in Esperion Therapeutics during the second quarter valued at about $28,000. Traphagen Investment Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the third quarter worth about $27,000. National Bank of Canada FI boosted its stake in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at about $50,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.